A panel discussion of the challenges and standards of care for managing patients with multiple myeloma.
In 2017, the FDA approved 17 agents for new or expanded indications for hematologic malignancies, including one agent for anaplastic large cell...
Clinicians reveal the importance of screening for an underlying impaired immune response when patients present with rare symptoms.
The results show that triple therapy with ibrutinib, lenalidomide, and rituximab should be evaluated in a randomized controlled trial.
Researchers examine the long-term effects and safety of patients’ brains and autoimmune systems while receiving treatment with rituximab.
Patients outside the United States will be able to access the drug only through compassionate use programs.
A systematic review and meta-analysis confirms that HDT/ASCT is still the best option for newly-diagnosed multiple myeloma.
According to a 2-decade-old study, patients with mycosis fungoides have a higher risk of developing secondary solid tumors based on patient...
ASH President Kenneth C. Anderson, MD, and ASH Secretary Robert A. Brodsky, MD, gave a preview of four practice-changing studies.
Although nonobesity related cancer cases are declining in the U.S., the rate of obesity-related cancer is not due to an increasingly...